⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBIO News
iBio, Inc. Common Stock
Integrated Biosciences Appoints Tony Wu, Co-Founder of xAI, to its Scientific Advisory Board
businesswire.com
IBIO
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
Dr. Emil Lou, Intima Bioscience Principal Investigator, Named to 2026 TIME100 Health List
prnewswire.com
IBIO
IntraBio Reports Further Detail on Positive Data from Levacetylleucine Pivotal Trial for the Treatment of Ataxia-Telangiectasia
businesswire.com
IBIO
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
globenewswire.com
IBIO
IntraBio obtient l’autorisation de la Commission européenne pour AQNEURSA ® dans le traitement de la maladie de Niemann-Pick de type C
businesswire.com
IBIO
IntraBio riceve dalla Commissione europea l'approvazione di AQNEURSA ® per il trattamento della malattia di Niemann-Pick di tipo C
businesswire.com
IBIO
イントラバイオ、欧州委員会から承認を取得 AQNEURSA ® ニーマン・ピック病C型の治療のための
businesswire.com
IBIO
IntraBio erhält Zulassung der Europäischen Kommission für AQNEURSA ® zur Behandlung der Niemann-Pick-Krankheit Typ C
businesswire.com
IBIO
IntraBio annonce les résultats positifs de son essai pivot sur la lévacétylleucine dans le traitement de l’ataxie télangiectasie
businesswire.com
IBIO